News

Collaborative by Nature

Tuesday, October 10, 2017

 

Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summits PhaseOut DMD Clinical Trial

Thursday, October 05, 2017

CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society

 
Continue Reading

MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel Bone-Targeted Combination Treatment for Osteosarcoma

Thursday, October 05, 2017

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $2M Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to build upon the success of the Phase I grant—demonstration of in vivo efficacy in model systems of osteosarcoma. The new work will focus on optimizing the method of use and testing the drug combination in spontaneous canine osteosarcoma.  

Smart, Hard-Working and Happy

Monday, October 02, 2017

 

2017 Rocky Mountain Life Science Investor and Partnering Conference welcomes 40 investors and strategic partners

Friday, September 29, 2017

 

AlloSource Strives to Advance Healing

Tuesday, September 26, 2017

 

dBMEDx Announces Supply Agreement with Direct Supply

Monday, September 25, 2017

dBMEDx, Inc., a privately-held, wireless medical device company, announced today that it has entered into a definitive supply agreement with Direct Supply®, the nation’s leading provider of equipment for the Senior Living market. Under the agreement, dBMEDx will integrate their proprietary bladder scanning technology into a new Direct Supply® device to create the first wireless bladder scanner optimized for use in long term care settings.
 
Continue Reading

AmideBio Awarded NIH SBIR Phase 1 Grant to Study Novel Glucagon for the Treatment of Hyperinsulinism

Monday, September 25, 2017

AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received a $338,387 Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Health. Under the 2 year grant, AmideBio will develop and produce a series of solution-stable glucagons and test them both in vitro and in vivo with the goal of identifying a glucagon analog suitable for clinical testing for long term treatment of hyperinsulinism, a disease whereby infants and new born babies suffer from persistant hypoglycemia which can lead to seizures and brain damage. A solution-stable glucagon would also have benefit in the treatment of emergency hypoglycemia.

Glucagon has been shown to be an effective treatment option for hyperinsulinism but its inherent instability has limited its therapeutic use due to complications associated with its administration through pumps. Using AmideBio’s BioPure™ process, the Company has produced glucagon analogs that have in-use stability of at least 6 months at 40°C and extended long term storage that meets the standard 95% potency requirement throughout 2-year storage at 4°C. These analogs will be suitable for use in a pump system for long-term management of severe persistent hyperinsulinism. Under the grant, these analogs will be further refined and tested.

“This grant will allow us to further develop and test AmideBio’s stable glucagons for treatment of patients with hyperinsulinism who fail to respond to current drug treatments,” said Misha Plam, CEO of AmideBio. “This therapeutic solution offers the potential for babies to avoid traumatic surgeries including a total pancreatectomy, providing the chance for them to live more normal lives.”

 
Continue Reading

Cetya Therapeutics Announces STTR Grant Award

Friday, September 22, 2017

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease

 
Continue Reading

Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test

Friday, September 22, 2017

Blood-based test offers more precise treatment prognosis to inform treatment choice, improve physician-patient communication, and address payment program quality measures
 
Continue Reading